Trials / Completed
CompletedNCT00599274
Study to Determine if Avonex and Rebif Work Comparably Well in Subjects With Relapsing Multiple Sclerosis
A Multicenter, Prospective and Retrospective, Long-Term Observational Study of AVONEX® and Rebif® to Determine the Efficacy, Tolerability, and Safety in Subjects With Relapsing Multiple Sclerosis (MS)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 136 (actual)
- Sponsor
- Biogen · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to find out if weekly Avonex works as well as three times a week Rebif in subjects with relapsing multiple sclerosis.
Detailed description
This is a Phase 4, multicenter, prospective and retrospective, long-term observational study of Avonex® and Rebif® to determine the efficacy, tolerability, and safety in subjects with relapsing MS.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Interferon beta-1a | injection once a week |
| DRUG | Interferon beta-1a | injection three times a week |
Timeline
- Start date
- 2002-08-01
- Completion
- 2003-05-01
- First posted
- 2008-01-23
- Last updated
- 2010-01-27
Locations
11 sites across 4 countries: United States, Australia, Austria, Canada
Source: ClinicalTrials.gov record NCT00599274. Inclusion in this directory is not an endorsement.